Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data.

CONCLUSIONS: The overall SVR12 rates in our study were comparable with those in previous pivotal trials. DAAs are generally safe. The interaction of HBV and HCV during DAA therapy and the observation of de novo HCC development and HCC recurrence during or after DAAs warrants additional studies.
PMID: 30316726 [PubMed - as supplied by publisher]

Source: Journal of Microbiology, Immunology, and Infection - September 26, 2018 Category: Microbiology Authors: Hong CM, Liu CH, Su TH, Yang HC, Chen PJ, Chen YW, Kao JH, Liu CJ Tags: J Microbiol Immunol Infect Source Type: research